NCT04292899: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT04292899 |
---|---|
Title | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | March 6, 2020 |
Completion date | April 9, 2020 |
Required reporting date | April 9, 2021, midnight |
Actual reporting date | Dec. 15, 2020 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |